---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-022227"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:10:30.475867+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Celcuity prices $60M common stock offering of 3.871M shares at $15.50

## Summary
- 3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.
- Proceeds to fund working capital, R&D, and Phase 3 trial of gedatolisib for HR+/HER2- advanced breast cancer.
- Investors include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital, Blue Owl Healthcare.
- Offering closed May 31, 2024; existing cash plus proceeds expected to fund operations through at least H2 2026.

## SEC filing metadata
- accession: 0001493152-24-022227
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/0001493152-24-022227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315224022227/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-022227
- JSON: https://secwatch.observer/filing/0001493152-24-022227.json
- Plain text: https://secwatch.observer/filing/0001493152-24-022227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.